Friday, November 20, 2026

Vaxdigm Selected for 800 Million Won Ministry of Health and Welfare Project... to Build AI Vaccine Design Platform

Input
2026-11-20 09:03:07
Updated
2026-11-20 09:03:07
Vaxdigm CEO SungJae Kim. Provided by Vaxdigm
[Financial News] Vaxdigm has won a national project from the Ministry of Health and Welfare and will develop a vaccine design platform using generative artificial intelligence (AI). The company plans to combine its proprietary protein expression technology with AI-based antigen design technology to improve research efficiency, from identifying vaccine candidates through experimental validation.
Vaxdigm said on the 20th that it had been selected as the lead research and development institution for the “Advanced Bio-Convergence Talent Development (R&D)” project, promoted by the Ministry of Health and Welfare and managed by the Korea Health Industry Development Institute.
The project, titled “Building a Generative AI-Based Vaccine Library Design Platform by Attracting AI-Bio Convergence Talent,” will run for 24 months, from July 2026 through June 2028. The total research and development budget is 800 million won, of which 600 million won is government funding.
The research centers on combining the company’s proprietary protein expression technology, “ChaperNova,” with generative AI-based antigen design technology. ChaperNova is a platform that produces target proteins by improving their structural stability and soluble expression. Vaxdigm plans to link the two technologies to establish a research framework spanning antigen design, protein expression and experimental validation, and to secure a range of candidate antigens.
To this end, the company has newly hired three PhD-level specialists in AI. Its research into AI-based candidate discovery and vaccine library development, underway since 2024, will also be expanded to the platform-enhancement stage. The company aims to reduce research and development time and costs by integrating AI-based design and prediction technologies into its existing experiment-centered research.
The company is also building its technological foundation. Three core technologies related to ChaperNova, covering protein expression and nanoparticle manufacturing, were registered as patents in Japan last September.
Vaxdigm CEO and principal investigator SungJae Kim said, “By integrating generative AI with our existing core technology for rapid vaccine development, we will strengthen our ability to respond to emerging and variant infectious diseases,” adding, “We plan to expand the AI-convergence technologies we have developed in the vaccine field into high-value-added biomaterials.”

[email protected] Jung Sang-hee Reporter